The official report on the International Patient Advocacy Symposium on Brain Metastases is available here:
https://t.co/H3BKQTqF1u
#brainmetastases#brainmets#braintumour
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation https://t.co/QMLXAi7NEN
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
https://t.co/NSaYkpUmzm
Our thoughts are with the loved ones of Dr Stu Farrimond, who has sadly passed away.
We are so grateful for everything he did to raise awareness of this cruel disease & fight for better outcomes for those affected.
@theIBTA#BrainTumourResearch#TogetherWeWillFindACure
The GLIORESOLVE project was featured in the 2024/2025 World Edition of the Brain Tumour Magazine, published by the @theIBTA You can read the full publication here https://t.co/kXO0k0q8zX and our article is on Pg 23!
The #EUCancerPlan has been a success for member states, yet so much remains to be done. 👈
Inequalities in reach and accessibility of cancer care persist. The solution: concrete, data-driven insights to drive robust policy action. 📈
The #EuropeanCancerPulse provides vital information that governments, organisations and advocates need to identify weak points and act on them. 💻
Take a look. 🔗 https://t.co/4FNdocG4TR
Read our country reports and see for yourself. 📃 https://t.co/IEm2zi8LOM
🚀 We are proud to announce that @sisaqol final recommendations are here!
🎗️This global initiative, co-led by EORTC & @Boehringer, sets new standards for analysing patient-reported outcomes in cancer trials.
Learn more: https://t.co/XNXDq28ZmN
#CancerResearch#QualityofLife